SCHEMBL4674940

SCHEMBL4674940

Cc1ccc(Cn2cc(C(=O)C=C(O)c3nc[nH]n3)cn2)cc1

nearest known ligand 0.42

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 16/20 0.42
HSD17B10 Q99714 1/20 0.39
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 1/20 0.37
POLB P06746 1/20 0.36
KLK1 P06870 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672485 0.91 HSD17B10 (0.40) KLKB1HSD17B10ALDH1A1KDM4EKLK1
SCHEMBL4671994 0.91 KDM4E (0.40) KLKB1HSD17B10ALDH1A1KDM4EKLK1
SCHEMBL4678760 0.90 KLKB1 (0.41) KLKB1HSD17B10ALDH1A1POLB
SCHEMBL4675754 0.90 L3MBTL1 (0.45) KLKB1HSD17B10
SCHEMBL4672069 0.90 LMNA (0.43) KLKB1HSD17B10ALDH1A1KDM4E
SCHEMBL4672090 0.88 KLKB1 (0.38) KLKB1HSD17B10ALDH1A1KDM4EPOLB
SCHEMBL4676023 0.83 KLKB1 (0.42) KLKB1HSD17B10ALDH1A1POLBKLK1
SCHEMBL4671883 0.82 KLKB1 (0.34) KLKB1ALDH1A1KDM4EPOLB
SCHEMBL4676296 0.82 SCD (0.44) KLKB1POLB
SCHEMBL4672332 0.81 SMN1; SMN2 (0.38) ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 KLKB1 3843/4885HSD17B10 241/4885ALDH1A1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.